KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short term Debt (2019 - 2025)

Royalty Pharma's Short term Debt history spans 7 years, with the latest figure at $380.0 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 61.92% year-over-year to $380.0 million; the TTM value through Dec 2025 reached $380.0 million, down 61.92%, while the annual FY2025 figure was $380.0 million, 61.92% down from the prior year.
  • Short term Debt for Q4 2025 was $380.0 million at Royalty Pharma, roughly flat from $380.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $999.4 million in Q2 2025 and bottomed at $105.7 million in Q3 2022.
  • The 5-year median for Short term Debt is $380.0 million (2025), against an average of $533.7 million.
  • The largest annual shift saw Short term Debt skyrocketed 824.19% in 2022 before it plummeted 61.92% in 2025.
  • A 5-year view of Short term Debt shows it stood at $107.9 million in 2021, then surged by 824.19% to $997.5 million in 2022, then grew by 0.19% to $999.4 million in 2023, then decreased by 0.16% to $997.8 million in 2024, then tumbled by 61.92% to $380.0 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Short term Debt are $380.0 million (Q4 2025), $380.0 million (Q3 2025), and $999.4 million (Q2 2025).